**Clinical Pharmacogenetics Implementation Consortium Guideline for *CYP2D6, ADRB1*, *ADRB2, GRK4,* and *GRK5* Genotypes andBeta-Blocker Therapy**

Julio D. Duarte,1,2 Cameron D. Thomas,1,2 Craig R. Lee,3 Rachel Huddart,4 Jose A.G. Agundez,5 Jordan F. Baye,6 Andrea Gaedigk,7 Teri E. Klein,4 David E. Lanfear,8,9 Andrew A. Monte,10 Mohamed Nagy,11,12 Matthias Schwab,13, 14, 15 C. Michael Stein,16, 17 Chakradhara Rao S. Uppugunduri,18, 19 Ron H.N. van Schaik,20 Roseann S. Gammal,21,22 Kelly E. Caudle,22 Jasmine A. Luzum8,23

1. Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA
2. Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, USA
3. Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA
4. Department of Biomedical Data Science, Stanford University, Stanford, CA, USA
5. University of Extremadura, Institute of Molecular Pathology Biomarkers, Cáceres, Spain
6. Department of Pharmacy Practice, South Dakota State University College of Pharmacy & Allied Health Professions, Brookings, SD, USA
7. Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children’s Mercy Research Institute and School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA
8. Center for Individualized and Genomic Medicine Research (CIGMA), Henry Ford Hospital, Detroit, MI, USA
9. Heart and Vascular Institute, Henry Ford Health, Detroit, MI, USA
10. Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
11. Department of Pharmaceutical Services, Children’s Cancer Hospital Egypt 57357, Cairo, Egypt
12. Personalized Medication Management Unit, Children’s Cancer Hospital Egypt 57357, Cairo, Egypt
13. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
14. Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany
15. Departments of Biochemistry and Pharmacy, University Tuebingen, Tuebingen, Germany
16. Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
17. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
18. Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland
19. Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland
20. Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, The Netherlands
21. Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
22. Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA
23. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA

**Corresponding Author:**

Julio D. Duarte, Pharm.D., Ph.D., FAHA

University of Florida College of Pharmacy

HSC PO Box 100486, 1600 SW Archer Rd

Gainesville, FL 32610

Tel: 352-273-8132

Fax: 352-273-6121

Email: [juliod@cop.ufl.edu](mailto:juliod@cop.ufl.edu); [contact@cpicpgx.org](mailto:contact@cpicpgx.org)

**Word Counts:**

Abstract (250 limit): 153

Text (4,000 limit): 3,655

References (50 limit): 56

Figures/tables (5 limit): 2

**Keywords:**

ADRB1, ADRB2,atenolol,beta-blocker, betaxolol, bisoprolol, carvedilol, CPIC, CYP2D6, GRK4, GRK5, labetalol, metoprolol, nebivolol, pharmacogenetics, pharmacogenomics, propranolol

**Conflicts of Interest:**

A.G. is the director of PharmVar. D.E.L. is a consultant for Janssen, Ortho Diagnostics, Cytokinetics, Astra Zeneca, Otsuka, Abbot Laboratories, Illumina, has participated in research from Amgen, Lilly, Astra Zeneca, Pfizer, Bayer, Illumina, Somalogic and Janssen, and has a patent (held by Henry Ford Health) for a beta blocker response polygenic score. All other authors declare no competing interests for this work.

**Funding:**

This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264 and U24HG010135) and PharmGKB (U24HG010615). Additional grant funding includes R01HG011800 (J.D.D.), K08HL146990 (J.A.L.), the Robert Bosch Stiftung Stuttgart, Germany (M.S.), R35 GM131770 (CMS), P50MD017351 (D.E.L.) and R01HL132154 (D.E.L.).

**ABSTRACT**

Beta-blockers are widely used medications for a variety of indications, such as heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., *CYP2D6*) and pharmacodynamic (e.g., *ADRB1*, *ADRB2*, *GRK4*, *GRK5*) genes have been studied in relation to beta-blocker exposure and response. We searched and summarized the strength of the evidence linking beta-blocker exposure and response with the five genes listed. The level of evidence was high for associations between *CYP2D6* genetic variation and both metoprolol exposure and heart rate response. Evidence indicates that CYP2D6 poor metabolizers have clinically significant increased exposure and reduced heart rate in response to metoprolol compared to those who are not CYP2D6 poor metabolizers. Therefore, we provide therapeutic recommendations regarding genetically predicted CYP2D6 metabolizer status and metoprolol therapy. However, there was insufficient evidence to make therapeutic recommendations at this time for other beta-blockers and *CYP2D6* or any beta-blocker and the other four genes evaluated (updates at [www.cpicpgx.org](http://www.cpicpgx.org)).

**INTRODUCTION**

Beta-blockers are widely used medications for the treatment of a variety of cardiovascular and non-cardiovascular indications, such as heart failure, ischemic heart disease, hypertension, cardiac arrhythmias, anxiety, and glaucoma. Certain beta-blockers are extensively metabolized by the hepatic cytochrome P450 2D6 (CYP2D6) enzyme to mostly inactive metabolites (except for carvedilol, which is metabolized by CYP2D6 into both pharmacologically active and inactive metabolites) (**Table S1**). *CYP2D6* genotypes have been linked to variability in plasma levels of some beta-blockers, with higher circulating beta-blocker plasma concentrations potentially leading to more pronounced effects on vital signs such as heart rate and blood pressure. In addition, genetic variation in the pharmacodynamic genes *ADRB1*, *ADRB2*, *GRK4*, and *GRK5* have also been studied in relation to beta-blocker pharmacodynamics and clinical response, though the clinical implications of such variation are unclear. The purpose of this guideline is to provide clinicians with information that facilitates the interpretation of clinical genotyping test results to guide beta-blocker prescribing and to discuss the evidence linking genetics to beta-blocker exposure and response. Detailed guidelines for the use of beta-blockers, reflections on the cost-effectiveness of genotyping, and whether to order a genotype test prior to beta-blocker prescribing are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines are periodically updated at [www.cpicpgx.org/guidelines/](http://www.cpicpgx.org/guidelines/).

**FOCUSED LITERATURE REVIEW**

A systematic literature review focused on the link between *CYP2D6*, *ADRB1*, *ADRB2*, *GRK4*, and *GRK5* genotypes and beta-blocker exposure and response was conducted (details in **Supplemental Material**). The literature search included different variations of the drug class name as well as the following specific beta-blocker names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, celiprolol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, and sotalol (**Table S1**). The evidence for all five genes and all beta-blockers evaluated are summarized in **Tables S2-S5**.

**GENES: *CYP2D6*, *ADRB1*, *ADRB2*, *GRK4*, AND *GRK5***

**Background**

***CYP2D6.*** *CYP2D6* is a highly polymorphic gene (1), with over 160 haplotypes (or star (\*) alleles) defined by the Pharmacogene Variation (PharmVar) Consortium to date (2) (see ***CYP2D6* Allele Definition Table** online (3, 4)). The frequencies of these star alleles differ significantly across ancestrally diverse populations (see ***CYP2D6* Allele Frequency Table** online (3, 4)). Alleles are categorized into predicted enzyme function groups with activity values ranging from 0 to 1 as follows: normal function (activity value 1; e.g., *CYP2D6\*1* and *\*2*), decreased function (activity value 0.25, e.g., *CYP2D6\*9*, *\*10*, and *\*41* or 0.5, e.g., *\*17* and *\*29*), and no function (activity value 0; e.g., CYP2D6*\*3-\*6*) (**Table 1**). Given that *CYP2D6* is prone to structural variation, including gene deletions, duplications, multiplications, and rearrangements with the pseudogene *CYP2D7*, clinical laboratories often report *CYP2D6* copy number variants. Notably, *CYP2D6\*5* represents a gene deletion, whereas gene duplications and multiplications are denoted using “xN” (e.g., *CYP2D6\*1x2* indicates two gene copies while *CYP2D6\*1xN* denotes the presence of two or more gene copies). Clinical allele function, as described in the ***CYP2D6* Allele Functionality Table**, was determined based on reported *in vitro* and/or *in* *vivo* data when available (3, 4).

***ADRB1.*** *ADRB1* encodes the beta-1 adrenergic receptor, which is antagonized by both “beta-1 selective” (e.g., metoprolol, atenolol) and “non-selective” (e.g., carvedilol, labetalol, propranolol) beta-blockers. The beta-1 adrenergic receptor is a G-protein-coupled receptor that stimulates intracellular cyclic adenylyl monophosphate (cAMP) generation in response to catecholamines (e.g., epinephrine, norepinephrine). Beta-1 adrenergic receptors are primarily expressed in cardiac tissue and thus mediate chronotropic, dromotropic, and inotropic effects from sympathetic nervous system activation in the heart (5). In the heart, endogenous catecholamine-induced receptor activation (and the subsequent cAMP generation) initiates a calcium-mediated signaling cascade that results in increased cardiac contractility and rate of contraction (6). Beta-1 adrenergic receptor activation in renal, vascular, and adipose tissues also mediates important physiological events, including renin release, vasodilation, and lipolysis (7-9). Sustained beta-1 receptor stimulation, which results in receptor desensitization and down-regulation, plays a key role in the development and progression of cardiovascular disease (10, 11). The two most extensively studied *ADRB1* variants include the missense variants rs1801252 (c.145A>G; p.Ser49Gly) and rs1801253 (c.1165G>C; p.Gly389Arg). The Gly49 allele increases agonist-promoted desensitization of the beta-1 adrenergic receptor, while Gly389 decreases the efficiency of G-protein coupling (10). Both alleles produce the net effect of decreasing adenylyl cyclase activity, which results in decreased cAMP production.

***ADRB2.*** *ADRB2* encodes the beta-2 adrenergic receptor, another G-protein-coupled receptor that functions via a similar mechanism as the beta-1 receptor. The beta-2 receptor is antagonized at clinically used doses by “non-selective” beta-blockers, such as carvedilol, labetalol, and propranolol. This receptor is primarily expressed in bronchial smooth muscle cells, but is also expressed in cardiomyocytes and vascular smooth muscle cells. Like the beta-1 adrenergic receptor, activation of the beta-2 adrenergic receptor by catecholamines stimulates intracellular signaling of adenylate cyclase to produce cAMP. Activation of beta-2 adrenergic receptors in bronchial smooth muscle results in bronchodilation, and activation in cardiomyocytes also potentiates chronotropic, dromotropic, and inotropic effects. The two frequent and most studied *ADRB2* variants are rs1042713 (c.46G>A; p.Gly16Arg) and rs1042714 (c.79G>C; p.Glu27Gln). The Gly16 allele potentiates agonist-promoted receptor downregulation (decreasing cAMP production), while Glu27 produces resistance to agonist-promoted downregulation (increasing cAMP production) (12-14).

***GRK4.*** G protein-coupled receptor kinases (GRK) desensitize activated G protein-coupled receptors, including the beta-1 and beta-2 adrenergic receptors, ultimately leading to receptor down-regulation (15). Agonist-occupied G protein-coupled receptors are deactivated via intracellular phosphorylation by GRKs and lead to beta-arrestin-mediated receptor desensitization (15). There are seven known GRK isoforms, and GRK4 and GRK5 are the most studied with regard to beta-blocker pharmacogenetics. *GRK4* encodes the G protein-coupled receptor kinase 4 and is primarily expressed in the testes and brain. The two most commonly studied variants in *GRK4*, rs1024323 (c.425C>T; p.Ala142Val) and rs1801058 (c.1457T>C; p.Val486Ala), enhance agonist-promoted desensitization of beta-adrenergic receptors, leading to decreased intracellular cAMP production (16).

***GRK5.*** *GRK5* encodes the G protein-coupled receptor kinase 5, and it is expressed in cardiovascular tissues (17). The rs2230345 (c.122A>T; p.Gln41Leu) variant potentiates agonist-promoted beta-receptors desensitization, ultimately decreasing the production of cAMP (18).

**Genetic Test Interpretation**

***CYP2D6.*** Clinical laboratories typically interrogate *CYP2D6* genetic variants of known functional consequences and appreciable frequencies in the general population. Genotypes are assigned using star (\*) allele nomenclature which can be found at the PharmVar website (https://www.pharmvar.org/gene/CYP2D6). Each star allele (or haplotype) represents a specific combination of variants identified by the gene test. The combination of inherited alleles (maternal and paternal) determines a person’s diplotype, also referred to as genotype (e.g., *CYP2D6\*1/\*4*). Tables on the CPIC and PharmGKB websites contain lists of known *CYP2D6* alleles, the combinations of variants that define each allele, allele function, and reported allele frequencies across major ancestral populations (3, 4). Unlike other pharmacogenes, discerning gene copy number is essential for the accurate genetic prediction of an individual’s CYP2D6 phenotype. **Table 1** defines each predicted phenotype based on CYP2D6 activity score and provides example diplotypes. See the ***CYP2D6* Diplotype-Phenotype Table** online for a complete list of possible diplotypes and the corresponding predicted metabolizer phenotype assignments (3, 4). *CYP2D6* genotype to phenotype translation has been standardized by CPIC and the Dutch Pharmacogenetics Working Group (19). For more details on interpreting *CYP2D6* test results, including activity score calculations, please see the **Supplemental Material** (Genetic Test Interpretation Section).

***ADRB1*, *ADRB2, GRK4,* and *GRK5.*** To date, no standardized genotype to phenotype translation or phenotype terms have been proposed for *ADRB1*, *ADRB2*, *GRK4*, or *GRK5*. Rather, variants are denoted by either their unique rs number and the bases at that location defining the genotype (e.g., C/C) or the corresponding amino acid that is associated with missense variations (e.g., 389Arg/Arg). Clinical testing of these four genes is available commercially both as individual tests and as part of larger test panels.

**Available Genetic Test Options**

See the **Supplemental Material** and the Genetic Testing Registry ([www.ncbi.nlm.nih.gov/gtr/](http://www.ncbi.nlm.nih.gov/gtr/)) for more information on commercially available clinical testing options.

**Incidental Findings**

Currently, there are no diseases or conditions that have been consistently linked to variation in the *CYP2D6* gene independent of drug metabolism or drug response. *CYP2D6* variation may affect a patient’s response to several drugs, many of which are discussed in CPIC guidelines ([www.cpicpgx.org/guidelines/](http://www.cpicpgx.org/guidelines/)). Likewise, there are no diseases or conditions that have been consistently linked to the aforementioned variants in *ADRB1*, *ADRB2*, *GRK4*, or *GRK5*. Several studies have reported associations between *ADRB2* genotype and response to long-acting beta-2 adrenergic receptor agonists in patients with asthma (20).

**Other Considerations**

The evidence review assessed the independent effects of each individual genetic variant, or haplotypes containing two or more genetic variants, as opposed to the additive or interactive effects of multiple genetic variants together. Recent evidence from patients with heart failure indicates that the long-term benefit from beta-blockers may be polygenic (21, 22). As more evidence for the polygenic effects on beta-blocker response becomes available, these will be evaluated for future guidelines. Other types of higher order interactions, such as drug-drug-gene interactions, gene-environment interactions, and epigenetics, were not assessed in most of the studies evaluated, and hence, were also not evaluated in this guideline.

**DRUGS: BETA-BLOCKERS**

**Background**

Beta-blockers, also known as beta adrenergic receptor antagonists, are a class of drugs used for both cardiac (e.g., angina pectoris, cardiac arrhythmias, hypertension, myocardial infarction, heart failure) and non-cardiac indications (e.g., anxiety, essential tremor, glaucoma, migraine prophylaxis). Metoprolol is the sixth most prescribed drug overall, with 66.4 million prescriptions in the U.S. in 2020 (23). Four other beta-blockers (carvedilol, atenolol, propranolol, and timolol) were also among the top 200 drugs prescribed in the U.S. in 2020. Beta-blockers are classified as beta-1 selective, or “cardioselective”, if they predominantly antagonize beta-1 receptors (primarily located in cardiac tissue) at clinically used doses, or they are classified as “non-selective” if they antagonize both the beta-1 and beta-2 receptors (primarily located in smooth muscle tissue, but also expressed in the heart). Examples of “non-selective” beta-blockers include carvedilol, labetalol, and propranolol; “beta-1 selective” agents include atenolol, betaxolol, bisoprolol, metoprolol, and nebivolol (**Table S1**). Notable adverse effects caused by beta-adrenergic receptor blockade include bradycardia, hypotension, fatigue, insomnia, dizziness, depression, erectile dysfunction, and acute bronchospasm.

**Linking Genetic Variability to Variability in Drug-Related Phenotypes**

The guideline writing committee conducted a systematic evaluation of the data linking genetic variation with beta-blocker exposure and response. Beta-blockers with applicable evidence available for evaluation included acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, and sotalol. The committee reviewed and graded the evidence related to associations with response to these drugs and the following genes: *CYP2D6*, *ADRB1*, *ADRB2*, *GRK4*, and *GRK5* (**Tables S2-S5**). This evidence was used to support the therapeutic recommendations provided below.

CYP2D6 appears to play a major role in the hepatic metabolism and elimination of several beta- blockers, most notably, metoprolol, carvedilol, nebivolol, and propranolol (**Table S1**). CYP2D6 poor metabolizers can experience several-fold higher plasma concentrations of metoprolol, carvedilol, and nebivolol following oral administration, compared to those who are not CYP2D6 poor metabolizers (24-28). Insufficient evidence exists to indicate whether propranolol systemic exposure is similarly higher in CYP2D6 poor metabolizers. The most extensive pharmacokinetic data and largest magnitude of pharmacogenetic effects relate to metoprolol, which is metabolized to mostly inactive metabolites. Compared with CYP2D6 normal metabolizers given the same dose, poor metabolizers experience greater than two-fold higher peak metoprolol plasma concentrations and elimination half-life, with a nearly five-fold increase in steady-state concentrations and area under the plasma concentration-time curve (AUC) (29). Of note, beta-blockers exhibit a sigmoid dose-response relationship. Thus, increasing beta-blocker plasma concentrations beyond a certain threshold does not result in further increases in response (30, 31).

Despite the observed pharmacokinetic differences in the above-listed beta-blockers, *CYP2D6* genotype-associated differences in pharmacodynamics and clinical response have only been consistently reported for metoprolol, and primarily related to heart rate and blood pressure response (32-35). Evidence suggests that the markedly increased metoprolol exposure experienced by poor metabolizers also leads to greater metoprolol-associated decreases in blood pressure (approximately 3-6 mmHg systolic; 2-6 mmHg diastolic) and heart rate (approximately 3-8 beats/min). This more exaggerated heart rate response to metoprolol in poor metabolizers may increase the risk of bradycardia, but few well-powered studies have assessed this risk (32, 33).

The two most-studied variants in *ADRB1*, p.Ser49Gly and p.Gly389Arg, both result in decreased cAMP production after beta-1 receptor stimulation *in vitro*, somewhat endogenously mimicking the effect of beta-blockers. Thus, patients with the p.Ser49 or p.Arg389 alleles would be expected to exhibit a greater pharmacologic response to beta-blockers. Nevertheless, the current evidence does not support that these variants affect either beta-blocker dosage requirements or heart rate, blood pressure, or echocardiographic indicators of beta-blocker response in patients (36-39). The data related to *ADRB1* and clinical outcomes in beta-blocker treated patients is more conflicting, particularly in heart failure (the patient population most studied). However, the writing committee noted a trend in the clinical outcomes evidence, depending on whether the studies evaluated beta-blocker response by dose level vs. as a binary variable (i.e., beta-blocker treatment yes/no). Of the studies that reported significant associations between p.Arg389 and p.389Gly and cardiovascular outcomes, nearly all of them accounted for beta-blocker dose in their analyses. Patients with the p.389Arg/Arg genotype experienced significantly worse outcomes than those with other genotypes when treated with low-dose beta-blockers (40-42). On the other hand, almost no studies that analyzed beta-blocker use as a binary variable (yes/no) reported these associations with clinical outcomes (43-45). Thus, it is possible that, if beta-blocker mediated cardiovascular outcomes differ by p.Arg389Gly genotype, titration to goal beta-blocker doses could abrogate the effect. However, the writing committee concluded that additional research is needed to discern and validate this observation before any clinical recommendations could be made (CPIC level C-no recommendation).

The committee found insufficient evidence to support associations between beta-blocker response and *ADRB2* genotype. However, fewer analyses of *ADRB2* variants are available in the literature compared with *ADRB1*, and pharmacogenetic interactions with *ADRB2* may depend on whether the beta-blocker in question is nonselective and therefore likely to inhibit the beta-2 receptor at clinically used doses. Even fewer studies were available related to *GRK4* and *GRK5* variants and their associations with beta-blocker response. Thus, no clinical recommendations were provided for variants in *ADRB2*, *GRK4*,or *GRK5* (CPIC level C-no recommendation).

**Therapeutic Recommendations**

The writing committee concluded that sufficient evidence was available to provide recommendations on how to use *CYP2D6* genotype information to guide the prescribing of metoprolol. Insufficient evidence was available to support recommendations for the other beta-blockers reviewed (CPIC level C-no recommendation; **Tables S6-S8**). Importantly, none of the recommendations provided in this guideline should be interpreted in a way that would prevent or impede the up-titration of beta-blocker doses to maximally tolerated or guideline-recommended levels, such as in heart failure with reduced ejection fraction and in the post-myocardial infarction setting.

***Metoprolol.***  The evidence supporting the association of *CYP2D6* genotype with the exposure and response to metoprolol included a variety of participants (e.g., healthy volunteers, hypertension, and heart failure). Therefore, it may be reasonable to assume that the pharmacokinetic effects of *CYP2D6* variation would affect clinical metoprolol response similarly across a variety of indications, and the dosing recommendations provided could be utilized for most cardiovascular indications (**Table 2**). Recommendations primarily focus on minimizing the risk of adverse effects in CYP2D6 poor metabolizers, given the evidence related to clinically significant increases in metoprolol systemic exposure leading to greater reductions in heart rate and blood pressure. While the evidence suggests metoprolol plasma concentrations are also increased in CYP2D6 intermediate metabolizers compared with normal metabolizers, these effects are smaller in magnitude than observed with poor metabolizers, and there was insufficient evidence to clarify whether these smaller pharmacokinetic differences alter clinical response. Most of the data available regarding associations between *CYP2D6* genotype and metoprolol response are related to oral formulations; limited evidence exists regarding pharmacogenetic effects with intravenous formulations.

***Carvedilol.*** While there is considerable evidence that CYP2D6 intermediate and poor metabolizers experience increased carvedilol exposure, there are far fewer reports in the literature (compared to metoprolol) assessing whether this translates to differences in heart rate or blood pressure response. CYP2D6 metabolizes carvedilol to both pharmacologically inactive and active metabolites, which may explain why significant differences in carvedilol exposure by CYP2D6 phenotype do not seem to consistently translate into significant differences in carvedilol clinical responses. The committee acknowledged the assessment from the U.S. Food and Drug Administration that CYP2D6 poor metabolizers may be at a higher risk of dizziness when given carvedilol (46), which may be based upon unpublished data; however, considering only published results, the writing committee felt there was insufficient evidence to support carvedilol dosing recommendations based on CYP2D6 phenotype (CPIC level C - no recommendation; **Table S6**).

***Pediatrics.*** Beta-blockers are used to treat a variety of indications in children, such as heart failure, hemangiomas, migraine, aggression, and anxiety. However, our literature search only identified two pediatric pharmacogenetic studies of beta-blockers (47, 48). Therefore, more evidence is needed before clinical recommendations can be specifically made for pediatric patients. It may be appropriate, with caution, to extrapolate the recommendations for CYP2D6 and metoprolol to most children because CYP2D6 activity correlates with *CYP2D6* genotype as early as two weeks of age (49, 50).

***Biogeographical groups.*** These recommendations are derived from studies that primarily included individuals of European ancestry as defined elsewhere (51). Although studies including individuals from other ancestry groups are needed, the effects of *CYP2D6* genetic variation on beta-blocker exposure or treatment outcomes are expected to be similar across biogeographic groups. However, selecting *CYP2D6* genetic tests that include variants present in the patient population being cared for is critical to ensure that phenotypes are accurately predicted (see the “Caveats” section below).

**Recommendations for Incidental Findings**

No recommendations for incidental findings have been provided given the lack of consistent evidence supporting associations between any of the assessed variants and inherited diseases or conditions independent of drug metabolism and response. For recommendations pertaining to other drugs potentially affected by *CYP2D6* variation, visit <https://cpicpgx.org/guidelines/> to review the appropriate CPIC guidelines.

**Other Considerations**

***Patients already receiving metoprolol.*** The therapeutic recommendations described above predominately apply to patients with genotypes predicting CYP2D6 poor metabolism who will be newly prescribed (or receiving a revised prescription for) metoprolol. However, because millions of patients are already prescribed metoprolol, it is expected that many patients already receiving metoprolol may later become aware of their predicted CYP2D6 phenotype. Metoprolol succinate (an extended-release formulation) plasma concentrations are expected to achieve steady-state in as soon as five days of daily dosing in the general population (52). Moreover, the most common adverse effects of metoprolol (e.g., bradycardia and hypotension) are dose-dependent and generally expected to occur soon after dose increases. Therefore, if a CYP2D6 poor metabolizer has already been tolerating stable metoprolol therapy, additional CYP2D6-associated adverse effects become less likely (assuming no changes in metoprolol dose or other health, medication, or lifestyle changes occur). Thus, modifying metoprolol therapy in CYP2D6 poor metabolizers on a well-tolerated regimen solely based on *CYP2D6* genotype is not necessary. This recommendation is primarily based on expert opinion and the clinical differences observed in CYP2D6 poor metabolizers after acute administration of metoprolol in very small studies (29).

***Drug-drug interactions and phenoconversion.*** Genetic test results do not consider other clinical characteristics of the patient that may also significantly affect CYP2D6 enzyme activity, i.e., a phenomenon referred to as “phenoconversion.” Drug-drug interactions are a common cause of phenoconversion (53). For example, a patient’s *CYP2D6* genetic test result may predict that they are a CYP2D6 normal metabolizer. However, if the concomitantly take another drug that strongly inhibits CYP2D6, their predicted phenotype would convert to poor metabolizer. As many as 30% of patients may be taking a concomitant CYP2D6 inhibitor leading to phenoconversion (53). CYP2D6 inhibitors are classified as strong, moderate, or weak (54). It is recommended to assume a CYP2D6 activity score of zero (i.e., poor metabolizer) in patients taking a concomitant strong inhibitor and to reduce the activity score by half in patients taking a moderate inhibitor. No activity score adjustment is suggested for weak inhibitors (55), and there are no known drugs that significantly induce CYP2D6 enzyme activity.

***Implementation of this guideline.*** The guideline supplement and CPIC website (3) contain resources that can be used within electronic health records (EHRs) to assist clinicians in applying genetic information to patient care for the purpose of drug therapy optimization (see *Resources to incorporate pharmacogenetics into an electronic health record with clinical decision support* in the **Supplemental Material**).

**POTENTIAL BENEFITS AND RISKS FOR THE PATIENT**

The potential benefit of using *CYP2D6* genotype data to guide metoprolol therapy is the avoidance of supratherapeutic plasma concentrations and associated decreased heart rate and blood pressure in CYP2D6 poor metabolizers. It would also potentially prevent patients from experiencing symptoms and adverse clinical effects related to this exaggerated response.

As with any laboratory test, a possible risk to patients is an error in genotyping or phenotype prediction. Such an error could lead to lower initial beta-blocker dosing. However, this risk is mitigated by recommendations (supported by this guideline) to up-titrate beta-blocker doses to either the dose maximally tolerated by the patient or to guideline-directed doses, when clinically appropriate.

**CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC TESTS**

As with any diagnostic test, *CYP2D6* genotype is just one factor that clinicians should consider when prescribing metoprolol. There can be important limitations to *CYP2D6* genetic testing. Targeted genotyping tests focus on interrogating previously described star (\*) alleles and therefore are not designed to detect novel variants. Furthermore, rare allelic *CYP2D6* variants may not be included in the targeted genotype test used, and patients with these rare variants may be assigned a metabolizer status that does not reflect their true phenotype. As such, alleles assigned by ‘default’, especially *CYP2D6\*1*, could potentially harbor an undetected genetic variant that results in altered metabolism and drug exposure. Many rare variants are predominantly found in non-European populations, increasing the likelihood of inaccurate phenotype assignments for non-European ancestry patients in the absence of testing. The Association for Molecular Pathology in collaboration with other professional organizations has published recommendations for a minimum set of variants that should be included in clinical genotyping assays for *CYP2D6* (56). As described in more detail above, phenoconversion of the genetically predicted CYP2D6 metabolizer status, due to non-genetic factors such as drug-drug interactions, is common and must also be considered with the genetic test results.

**DISCLAIMER**

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making, as well as to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health care provider to determine the best course of treatment for the patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC's guidelines, or for any errors or omissions.

**ACKNOWLEDGEMENTS**

We acknowledge the critical input of Dr. Mary V. Relling and members of the Clinical Pharmacogenetics Implementation Consortium (CPIC), funded by the National Institutes of Health. CPIC members are listed here: <https://cpicpgx.org/members/>.

# Table 1. Assignment of Predicted CYP2D6 Phenotype Based on Genotype

|  |  |  |  |
| --- | --- | --- | --- |
| **Phenotypea** | **Activity Score Range** | **Activity Score/Diplotypesb** | **Examples of *CYP2D6* Diplotypesb** |
| CYP2D6 ultrarapid metabolizer | >2.25 | >2.25 | *\*1/\*1xN, \*1/\*2xN, \*2/\*2xN*c |
| CYP2D6 normal metabolizer | 1.25≤x≤2.25 | 2.25  2.0  1.75  1.5  1.25 | *\*2x2/\*10*  *\*1/\*1, \*1/\*2*  *\*1/\*10x3*  *\*1/\*17, \*2/\*29*  *\*1/\*10, \*1/\*41, \*1/\*9* |
| CYP2D6 intermediate metabolizer | 0<x<1.25 | 1  0.75  0.5  0.25 | *\*1/\*5*  *\*10/\*17, \*29/\*41*  *\*10/\*10,\*41/\*41, \*10/\*41*  *\*4/\*10, \*4/\*41* |
| CYP2D6 poor metabolizer | 0 | 0 | *\*3/\*4, \*4/\*4, \*5/\*5, \*5/\*6* |
| CYP2D6 indeterminate | n/a | An individual carrying one or two uncertain function alleles | *\*1/\*22, \*1/\*25, \*22/\*25* |

n/a, not applicable

aSee the ***CYP2D6*** **Allele** **Frequency Table** for ancestry-specific allele and phenotype frequencies (3, 4).

bAssignment of allele function and allele activity values, including citations for allele function, can be found in the ***CYP2D6* Allele Definition Table** and the ***CYP2D6* Allele Functionality Table**. For a complete list of *CYP2D6* diplotypes and predicted phenotypes, see the ***CYP2D6*** **Diplotype to Phenotype Table** (3, 4).

cWhere *xN* represents the number of *CYP2D6* gene copies. For individuals with *CYP2D6* duplications or multiplications, see the **Supplemental Material** for additional information on how to translate diplotypes into phenotypes.

# Table 2. Dosing Recommendations for Metoprolol Based on CYP2D6 Phenotype

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Phenotype** | **Activity Score** | **Implicationsb** | **Recommendations** | **Classification of Recommendationsa** |
| CYP2D6 ultrarapid metabolizer | >2.25 | Increased metabolism of metoprolol leading to decreased drug concentrations; however, it is unclear whether this results in clinically significant changes in HR, BP, or clinical outcomes | No recommendation for metoprolol therapy due to insufficient evidence regarding diminished metoprolol effectiveness clinically | No recommendation |
| CYP2D6 normal metabolizer | 1.25≤x≤2.25 | Normal metabolism of metoprolol | Initiate standard dosing | Strong |
| CYP2D6 intermediate metabolizer | 0<x<1.25 | Decreased metabolism of metoprolol leading to increased drug concentrations; however, this does not appear to translate into clinically significant changes in HR, BP, or clinical outcomes | Initiate standard dosing | Moderate |
| CYP2D6 poor metabolizer | 0 | Decreased metabolism of metoprolol leading to markedly increased drug concentrations; this leads to greater HR and BP reductions, but the effect on clinical outcomes is unclear | Initiate therapy with lowest recommended starting dose. Carefully titrate dose upward to clinical effect or guideline-recommended dose; monitor more closely for bradycardia | Moderate |
| CYP2D6 indeterminate | n/a | n/a | No recommendation | No recommendation |

**a**Rating scheme described in **Supplemental Materials.**

bMetoprolol has no known active metabolites via CYP2D6.

**REFERENCES**

(1) Nofziger, C. *et al.* PharmVar GeneFocus: CYP2D6. *Clin Pharmacol Ther* **107**, 154-70 (2020).

(2) Gaedigk, A., Casey, S.T., Whirl-Carrillo, M., Miller, N.A. & Klein, T.E. Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. *Clin Pharmacol Ther* **110**, 542-5 (2021).

(3) CPIC. *CPIC® Guideline for Beta-blockers and CYP2D6, ADRB1, ADRB2, GRK4, and GRK5*. <<https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/>>. Accessed July 20 2022.

(4) PharmGKB. *Gene-Specific Information Tables for CYP2D6*. <<https://www.pharmgkb.org/page/cyp2d6RefMaterials>>. Accessed July 20 2022.

(5) Rohrer, D.K., Chruscinski, A., Schauble, E.H., Bernstein, D. & Kobilka, B.K. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. *J Biol Chem* **274**, 16701-8 (1999).

(6) Zaccolo, M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. *Br J Pharmacol* **158**, 50-60 (2009).

(7) Ablad, B., Carlsson, B., Carlsson, E., Dahlof, C., Ek, L. & Hultberg, E. Cardiac effects of beta-adrenergic receptor antagonists. *Adv Cardiol* **12**, 290-302 (1974).

(8) Fain, J.N. & Garcija-Sainz, J.A. Adrenergic regulation of adipocyte metabolism. *J Lipid Res* **24**, 945-66 (1983).

(9) Insel, P.A. & Snavely, M.D. Catecholamines and the kidney: receptors and renal function. *Annu Rev Physiol* **43**, 625-36 (1981).

(10) Sandilands, A.J. & O'Shaughnessy, K.M. The functional significance of genetic variation within the beta-adrenoceptor. *Br J Clin Pharmacol* **60**, 235-43 (2005).

(11) Bristow, M.R. *et al.* Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. *N Engl J Med* **307**, 205-11 (1982).

(12) Dishy, V. *et al.* The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. *N Engl J Med* **345**, 1030-5 (2001).

(13) Green, S.A., Turki, J., Bejarano, P., Hall, I.P. & Liggett, S.B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. *Am J Respir Cell Mol Biol* **13**, 25-33 (1995).

(14) Green, S.A., Turki, J., Innis, M. & Liggett, S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. *Biochemistry* **33**, 9414-9 (1994).

(15) Kohout, T.A. & Lefkowitz, R.J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol* **63**, 9-18 (2003).

(16) Felder, R.A. *et al.* G protein-coupled receptor kinase 4 gene variants in human essential hypertension. *Proc Natl Acad Sci U S A* **99**, 3872-7 (2002).

(17) Premont, R.T., Koch, W.J., Inglese, J. & Lefkowitz, R.J. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. *J Biol Chem* **269**, 6832-41 (1994).

(18) Liggett, S.B. *et al.* A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. *Nat Med* **14**, 510-7 (2008).

(19) Caudle, K.E. *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. *Clin Transl Sci* **13**, 116-24 (2020).

(20) Garcia-Menaya, J.M., Cordobes-Duran, C., Garcia-Martin, E. & Agundez, J.A.G. Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy. *Front Pharmacol* **10**, 520 (2019).

(21) Lanfear, D.E. *et al.* Polygenic Score for beta-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. *Circ Heart Fail* **13**, e007012 (2020).

(22) Lanfear, D.E. *et al.* Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank. *Circ Genom Precis Med*, e003835 (2023).

(23) ClinCalc. *The top 200 of 2020*. <<https://clincalc.com/DrugStats/Top200Drugs.aspx>>. Accessed June 8 2023.

(24) Goryachkina, K., Burbello, A., Boldueva, S., Babak, S., Bergman, U. & Bertilsson, L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. *Eur J Clin Pharmacol* **64**, 1163-73 (2008).

(25) Seeringer, A., Brockmoller, J., Bauer, S. & Kirchheiner, J. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. *Eur J Clin Pharmacol* **64**, 883-8 (2008).

(26) Zineh, I. *et al.* Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. *Clin Pharmacol Ther* **76**, 536-44 (2004).

(27) Guo, L. *et al.* Influence of CYP2D6\*5 and \*10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects. *J Clin Pharm Ther* **45**, 632-7 (2020).

(28) Lefebvre, J., Poirier, L., Poirier, P., Turgeon, J. & Lacourciere, Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. *Br J Clin Pharmacol* **63**, 575-82 (2007).

(29) Blake, C.M., Kharasch, E.D., Schwab, M. & Nagele, P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. *Clin Pharmacol Ther* **94**, 394-9 (2013).

(30) Rau, T. *et al.* Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. *Clin Pharmacol Ther* **92**, 21-8 (2012).

(31) Batty, J.A. *et al.* An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. *Clin Pharmacol Ther* **95**, 321-30 (2014).

(32) Bijl, M.J. *et al.* Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. *Clin Pharmacol Ther* **85**, 45-50 (2009).

(33) Meloche, M., Khazaka, M., Kassem, I., Barhdadi, A., Dube, M.P. & de Denus, S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis. *Br J Clin Pharmacol* **86**, 1015-33 (2020).

(34) Rau, T. *et al.* Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. *Clin Pharmacol Ther* **85**, 269-72 (2009).

(35) Thomas, C.D. *et al.* Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. *CPT Pharmacometrics Syst Pharmacol* **9**, 678-85 (2020).

(36) de Groote, P. *et al.* Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. *Pharmacogenet Genomics* **15**, 137-42 (2005).

(37) Luo, M., Bi, Y. & Xu, Y.X. Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure. *Chin Med J (Engl)* **120**, 1720-3 (2007).

(38) Mahesh Kumar, K.N., Ramu, P., Rajan, S., Shewade, D.G., Balachander, J. & Adithan, C. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population. *J Cardiovasc Pharmacol* **52**, 459-66 (2008).

(39) Metra, M. *et al.* Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. *Cardiovasc Drugs Ther* **24**, 49-60 (2010).

(40) Magnusson, Y. *et al.* Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. *Clin Pharmacol Ther* **78**, 221-31 (2005).

(41) Parikh, K.S. *et al.* Dose Response of beta-Blockers in Adrenergic Receptor Polymorphism Genotypes. *Circ Genom Precis Med* **11**, e002210 (2018).

(42) Guerra, L.A. *et al.* Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking beta-blockers. *Pharmacogenomics J* **22**, 62-8 (2022).

(43) Cresci, S. *et al.* Clinical and genetic modifiers of long-term survival in heart failure. *J Am Coll Cardiol* **54**, 432-44 (2009).

(44) Sehnert, A.J. *et al.* Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. *J Am Coll Cardiol* **52**, 644-51 (2008).

(45) Huang, J. *et al.* ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to beta-blockers in patients with heart failure. *Cell Discov* **4**, 57 (2018).

(46) U.S. Food and Drug Administration. *Table of Pharmacogenetic Associations*. <<https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2>>. Accessed April 26 2023.

(47) Van Driest, S.L. *et al.* Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. *J Pediatr* **222**, 213-20 e5 (2020).

(48) Wang, L., Zheng, K., Li, X., Wang, Y. & Xu, Q. Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma. *Biomed Res Int* **2020**, 8732871 (2020).

(49) Blake, M.J. *et al.* Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. *Clin Pharmacol Ther* **81**, 510-6 (2007).

(50) Leeder, J.S. *et al.* A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence. *Clin Transl Sci* **15**, 2514-27 (2022).

(51) Huddart, R. *et al.* Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. *Clin Pharmacol Ther* **105**, 1256-62 (2019).

(52) Aralez Pharmaceuticals US Inc. TOPROL-XL (metoprolol) [package insert]. U.S. Food and Drug Administration website. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019962s049lbl.pdf>. Assessed April 26, 2023.

(53) Cicali, E.J. *et al.* How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. *Clin Pharmacol Ther* **110**, 677-87 (2021).

(54) U.S. Food and Drug Administration. *Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers*. <<https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers>>. Accessed April 26 2023.

(55) Cicali, E.J., Smith, D.M., Duong, B.Q., Kovar, L.G., Cavallari, L.H. & Johnson, J.A. A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications. *Clin Pharmacol Ther* **108**, 116-25 (2020).

(56) Pratt, V.M. *et al.* Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. *J Mol Diagn* **23**, 1047-64 (2021).